|
|
|
|
|
by CogitoCogito
748 days ago
|
|
> How do you study mind-altering drugs when every clinical-trial participant knows they’re tripping? Are there really no protocols for research in which participants can tell whether they have received a certain drug or not? I mean sure I think that double-blind is best for research, but are there really not other cases in which they deal with the patients knowing? Edit: > By striving to cleave the drug’s effects from the context in which it’s given—to a patient by a therapist, both of whom are hoping for healing—blinded studies may fail to capture the full picture. Okay I see the issue is that patients not being blind to the treatment is (thought to be) necessary for the treatment to work. Okay yeah so that means it's hard to make the participants blind in anyway. Still I'm surprised there aren't approaches to deal with this. Of course it might mean by definition double-blind trials aren't possible, but then again maybe that's not always appropriate. I can see the pandora's box being opened by allowing drug studies to bypass these restrictions though so I guess I see why people don't like it. Later in the article: > In an email, an FDA spokesperson told me that blinded RCTs provide the most rigorous level of evidence, but “unblinded studies can still be considered adequate and well-controlled as long as there is a valid comparison with a control.” In such cases, the spokesperson said, regulators can take into account things like the size of the treatment effect in deciding whether the treatment performed significantly better than the placebo. |
|
Contrary to frequently-expressed opinion online, we are not in fact constrained to running only super-massive-sample-size triple-blind preregistered peer-reviewed gold-plated scientific studies and only permitted to say we might have an opinion if a metanalysis of multiple of those concurs. It's nice when we can do that, but the universe is not always so accommodating.